A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy

Summary

The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in relieving pain due to Diabetic Neuropathy.

Timeline

Start

2005-07

Primary completion

2006-06

Completion

2006-06

Outcome

Missed primary endpoint

registry analysis (unspecified test); Sativex vs Placebo; p = 0.634; estimated treatment effect -0.12 (95% CI -0.60 to 0.36); ANCOVA NCT00710424 ↗

registry analysis (unspecified test); Sativex vs Placebo; p = 0.521; Odds Ratio (OR) 0.857 (95% CI 0.537 to 1.370); Regression, Logistic NCT00710424 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nabiximols	Other / unclassified	—	—

Indications